Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Yanze YuHan ZengKaifeng JinRunze YouZhaopei LiuHongyi ZhangChunnan LiuXiaohe SuSen YanYuan ChangLi LiuLe XuJiejie XuYu ZhuZewei WangPublished in: Cancer immunology, immunotherapy : CII (2022)
Our study firstly identified and validated the clinical implications of NRP1 expression for prognosis and systematic therapeutic responses (PD-L1 blockade and ACT) in MIBC. NRP1 expression was associated with an immunosuppressive microenvironment with dysfunctional effector immune cells. Prospective investigations of its roles in the therapeutic landscape of MIBC warrant more consideration.